Daratumumab plus lenalidomide maintenance in newly diagnosed multiple myeloma after transplant: AURIGA subgroup analyses

Abstract In the primary analysis (32.3-month median follow-up) of the randomized, phase 3 AURIGA study (NCT03901963), daratumumab-lenalidomide (D-R) maintenance significantly improved MRD-negative conversion rates and reduced the risk of disease progression or death by 47% versus R maintenance in an...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Laahn Foster, Larry D. Anderson, Alfred Chung, Chakra P. Chaulagain, Erin Pettijohn, Andrew J. Cowan, Caitlin Costello, Sarah Larson, Douglas W. Sborov, Kenneth H. Shain, Rebecca Silbermann, Peter Voorhees, Maria Krevvata, Huiling Pei, Sharmila Patel, Vipin Khare, Annelore Cortoos, Robin Carson, Thomas S. Lin, Ashraf Badros
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2025-10-01
Colecção:Blood Cancer Journal
Acesso em linha:https://doi.org/10.1038/s41408-025-01355-0
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados